There are several points that can be inferred from these studies, namely that: (i) TAZ and YAP are able to promote an immunosuppressive environment via the direct upregulation of PD-L1 in NSCLC cells; (ii) TAZ and YAP may be utilized as predictive biomarkers for immune checkpoint inhibitors in NSCLC; and most importantly (iii) Combining TAZ/YAP-targeting agents with immune checkpoint inhibitors may be a promising therapeutic strategy for NSCLC patients (Figure 1). The gene discussed is CD274; the disease is non-small cell lung carcinoma.